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As tamoxifen stimulates ovarian steroidogenesis in premenopausal women, induces ovulation and increases the incidence of benign
ovarian cysts, there has been concern that it might also increase ovarian cancer risk in women treated premenopausally. In a national
case–control study in Britain, treatment histories were collected for 158 cases of ovarian cancer after breast cancer diagnosed at ages
under 55 years and 464 controls who had breast cancer at these ages without subsequent ovarian cancer. Risk of ovarian cancer was
not raised for women overall who had taken tamoxifen (odds ratio (OR)¼0.9, 95% confidence interval (CI) 0.6–1.3) or for those
treated when premenopausal (OR¼1.0, 95% CI 0.6–1.6) or perimenopausal (OR¼0.7, 95% CI 0.2–2.4). There was also no
relation of risk to daily dose, duration or cumulative dose of tamoxifen, or time since last use. There was, however, a significantly
raised risk in relation to non-hormonal chemotherapy. The results suggest that tamoxifen treatment of premenopausal or
perimenopausal women does not materially affect ovarian cancer risk, but that non-hormonal chemotherapy might increase risk.
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Tamoxifen, a non-steroidal anti-oestrogen, has been used success-
fully in the treatment of breast cancer since the early 1970s, and,
more recently, has been investigated as a prophylactic agent in
women at high risk of breast cancer. In premenopausal women,
however, tamoxifen induces ovulation (Messinis and Nillius, 1982),
stimulates ovarian steroidogenesis (Jordan et al, 1991), causes
ovarian enlargement (Gerhard and Runnebaum, 1979) and
increases the incidence of benign ovarian cysts (Powles et al,
1994). There has therefore been concern that it might increase the
risk of ovarian cancer in such women (Spicer et al, 1991). Studies
of ovarian cancer risk after tamoxifen treatment have been entirely
(Rutqvist et al, 1995) or largely (Cook et al, 1995; Curtis et al, 1996;
Fisher et al, 1998; Early Breast Cancer Trialists’ Collaborative
Group, 2005) based on postmenopausal women, with small
numbers, and without analyses for premenopausal women. We
therefore conducted a national case–control study in Britain to
investigate whether tamoxifen treatment of premenopausal women
affects their risk of ovarian cancer.
MATERIALS AND METHODS
With the appropriate ethical approval, data were extracted from
each of the population-based cancer registries in Britain except the
Northern registry, on all women with breast cancer occurring from
1983 to 1996, or to the most recent year of available data, if earlier.
The Northern registry, covering 5% of the population, was
excluded because the requisite data were not available. The
restriction to breast cancers incident since 1983 was because a pilot
investigation had shown that tamoxifen use at premenopausal ages
had been relatively uncommon before that year. The data extracted
included information on second cancers. Subjects in the registry
files were eligible as cases if they (i) had had a registered primary
breast cancer diagnosed during 1983–1996 below age 55 years, (ii)
at that time had had no previous or concurrent cancer, (iii) had
had a registered primary ovarian cancer diagnosed during 1988–
1996, at least 3 months after incidence of the breast cancer, with no
other second malignancy, except non-melanoma skin cancer or
breast cancer, occurring in the intervening period.
The controls were women with breast cancer diagnosed during
1983–1996 below age 55, selected from the same computer files as
the cases. Two controls were chosen per case, individually matched
on (1) date of incidence of the primary breast cancer, within 76
months, (2) age at incidence of the primary breast cancer, within
76 months, (3) registry region of residence at diagnosis of the
primary breast cancer, (4) survival without second cancer after
breast cancer diagnosis for the same length of time as that from
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ybreast cancer diagnosis to ovarian cancer diagnosis in the matched
case (‘the index duration’). Additionally, it was required that
controls (5) had not had an oophorectomy by the end of their
index duration after diagnosis of breast cancer and (6) had case-
notes that included the period up to the end of the index duration.
As the last two criteria could not be determined from the cancer
registry file, we examined the case-notes of potential controls
chosen on criteria (1–4), and if criterion (5) or (6) was not met (or
the case-notes could not be found), a replacement control was
chosen on criteria (1–4), with repetition as needed.
For each case and control, we extracted data from the hospital
case-notes on demography, the general practitioner, tamoxifen
treatment (start and stop dates, and dosage, for each period of
treatment), other treatments of the first primary cancer, abdominal
and pelvic radiotherapy before the first primary cancer, date of
diagnosis of the first and second cancers and histological type of
the ovarian cancer. Treatment histories for cases were included up
to the date of diagnosis of the second cancer. For matched
controls, they were included for the equivalent duration from
diagnosis of the first primary (i.e. for the ‘index duration’). For
subjects for whom tamoxifen data in the hospital notes were
incomplete, we contacted general practitioners to obtain more
complete information.
In parallel with the ovarian cancer study, case–control studies
of risks of several other cancers after breast cancer treatment
were conducted, using the same procedures and data extraction
forms. The controls from these studies who had not had an
oophorectomy met the general criteria to be controls for the
ovarian cancer cases, and we therefore used them as controls in the
present analyses, to maximise power. To include these controls, we
created matching strata for each of the critical variables (date and
age at breast cancer diagnosis, index duration and region of the
country), and assessed the effects of tamoxifen and other risk
factors on ovarian cancer risk by calculation of stratum-matched
odds ratios (ORs), as estimates of relative risks (and referred to as
such below). Odds ratios (ORs), 95% confidence intervals (CIs) for
the ORs, and trend tests were calculated by conditional logistic
regression (Breslow and Day, 1980). In addition, to check that the
results were not biased by addition of these extra controls, we
conducted matched reanalyses, by conditional logistic regression
(Breslow and Day, 1980), confined to the controls originally
collected to match the ovarian cancer cases. All statistical tests
were two-sided.
Because cancer registry data do not include menopausal status,
we included in the study all women diagnosed at ages under 55,
and after we had extracted data from the case-notes we divided the
subjects for analysis into (i) women known to be premenopausal,
or presumed to be so because they were aged under 45 at diagnosis
of breast cancer and of unstated menopausal status and (ii) women
stated to be postmenopausal or perimenopausal (we have referred
to these collectively in this study as perimenopausal, for simplicity,
as even the postmenopausal subjects were generally close to the
menopause (on average 4 years previously) because of the age
range of the study), and (iii) women aged 45 and older of unstated
menopausal status.
RESULTS
We identified 162 patients with ovarian cancer who met the study
criteria and for whom full case-notes were found. We also
identified 47 provisionally eligible case patients from cancer
registry records whose case-notes could not be located or who had
insufficient information for the study. Not all of these patients
would have been eligible if their notes had been located. The 47
excluded case patients were similar to the patients with full case-
notes with respect to age but slightly more likely to have been
diagnosed early in the study period. Of the 162 patients with full
case-notes available, at least one stratum-matched control patient
was found for 158 subjects, who formed the study cases.
Full case-notes were available, and extracted, for 464 eligible
controls in strata that contained any cases. We also identified 182
potential controls from cancer registry records whose full case-
notes could not be found. Some of these 182 subjects would have
been ineligible if the notes had been located and a record of
oophorectomy found. These 182 subjects were similar to the 464
controls with available notes with regard to age and slightly more
likely to have been diagnosed in the early years of the study.
Most cases and controls lived in England (Table 1). In 40% of
the cases, breast cancer had been diagnosed below age 45, and in
60% at ages 45–54. Two-thirds of the cases and over half of the
controls were known to have been premenopausal at breast cancer
diagnosis (89 cases, 227 controls) or were probably so because they
were aged below 45 years at breast cancer diagnosis and of
unknown menopausal status (10 cases, 24 controls). Fifty-four
percent of cases and 60% of controls had been treated with
tamoxifen.
The OR for ovarian cancer after tamoxifen was 0.9 (0.6–1.3) for
the subjects overall (Table 2), 1.0 (0.6–1.6) for those premeno-
pausal according to the criteria described in the Materials and
Methods, 0.9 (0.5–1.6) for women explicitly stated to be
premenopausal (not shown in the Table), and 0.7 (0.2–2.4) for
those perimenopausal (not shown in the Table). In analyses
restricted to matched controls (see Materials and methods), the
overall relative risk was 0.9 (0.5–1.4) (not shown in the table). The
risk in women who were premenopausal at breast cancer diagnosis
and had not received ovarian ablation radiation or alkylating
chemotherapy (i.e. breast cancer treatments that might cause
premature menopause) was 0.9 (0.5–1.6). There were too few
germ-cell tumours (2) to analyse this distinctive group separately.
Ovarian cancer risk showed no relation to duration, average
daily dose, cumulative dose, time since first use, or time since last
use of tamoxifen, either for the subjects overall (Table 2), or for
pre- or perimenopausal women separately. There were, however,
significantly raised risks for tamoxifen users for whom informa-
tion on dose, duration, or time since last treatment was
unavailable.
Risk of ovarian cancer was not related to non-tamoxifen
hormonal treatments (although few women had received such
treatments), but was significantly raised in those who had been
given non-hormonal chemotherapy (Table 3) and this remained
true after adjustment for tamoxifen use (OR¼1.8 (1.1–2.9); not in
table). The most frequently used non-hormonal chemotherapy was
the cyclophosphamide, methotrexate, fluorouracil (CMF) regimen,
for which ovarian cancer risk was similar to that for chemotherapy
overall. The next most common non-hormonal chemotherapy was
cyclophosphamide without methotrexate or fluorouracil. The number
of cycles of CMF was known for less than half of subjects receiving
this treatment and where known was almost always six, in cases
and controls. Risk of ovarian cancer was not related to radio-
therapy, which was generally to the breast, but occasionally was to
the ovary for ablation; two cases and no controls had received such
ablative radiotherapy at least 5 years ago (not in table).
Risk was not significantly related to smoking history, whether
parous, or use of hormone replacement therapy (which was
uncommon in this mainly premenopausal group), but increased
significantly with increasing weight (OR¼1.31 (1.05–1.63) per
10kg for all subjects; 1.51 (1.11–2.04) per 10kg for premenopausal
subjects) (not shown in table).
DISCUSSION
Tamoxifen stimulates the ovary when used premenopausally,
raising concern that it might increase the risk of ovarian cancer
(Spicer et al, 1991). This concern is heightened because tamoxifen
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Nillius, 1982), and clomiphene has been associated with raised
ovarian cancer risk in some studies (Rossing et al, 1994; Brinton
et al, 2004), although not others (Ness et al, 2002).
Ovarian cancer after breast cancer is not common, and previous
studies have been based on small numbers. One case–control
study has been published of ovarian cancer risk after tamoxifen
treatment, based on only 34 cases, of whom seven were
premenopausal. This found no increase in ovarian cancer, or
relation of risk to duration of treatment, but the CIs were wide
(Cook et al, 1995). Cohort studies of women aged 50 years or above
(Curtis et al, 1996) or postmenopausal women (Rutqvist et al,
1995) treated with tamoxifen did not show increased ovarian
cancer risk, but were based on small numbers of cancers in treated
women (20 and 22, respectively); the same was true for raloxifene
treatment (Neven et al, 2002). Two large follow-up studies of trials
patients, mainly aged 50 and above, did not analyse ovarian cancer
risk, but found similar numbers of ovarian cancers in the similar-
sized tamoxifen (11 cases) and placebo (10 cases) groups (Fisher
et al, 1998) or tamoxifen (25 cases) and control (22 cases) groups
(Early Breast Cancer Trialists’ Collaborative Group, 2005). A
cancer registry-based study that analysed hormonal treatment
overall, with incomplete follow-up and no data on the particular
drug or duration of treatment (Newcomb et al, 1999), found
ovarian cancer risk was not raised either in the first 5 years after
breast cancer or subsequently. The relationship between risk and
daily dose of tamoxifen does not appear to have been examined.
Our data show no effect of tamoxifen on risk of ovarian cancer
overall, no effect of dose or duration, and no relation to duration
since last use. The CIs for the dose and duration relations exclude
all but modest effects. Subanalyses by menopausal status,
identifying this as so-stated or based on age, did not show raised
risk for either premenopausal or perimenopausal women. The only
significant relationship with tamoxifen use was for the category
of unknown dose and duration of use. This is most unlikely to
represent a real effect, and is probably an artefact of the difficulty
of gaining detailed data for patients who have died several years
ago, who tend to be cases rather than controls. In our case–control
study of endometrial cancer risk after tamoxifen in the same
population (Swerdlow and Jones, 2005), for which there is a well-
established effect of tamoxifen on risk, cancer risks in users with
an unknown dose and duration of treatment were similar to those
in patients with known intermediate values of these variables. As
the unknown categories in the present study occurred in less than
10% of all subjects and under 15% of users, the effects on the
results for the known categories should have been minimal if any.
In principle, any tamoxifen-related risks of ovarian cancer might
be confounded by genetic factors, if breast cancers occurring in
patients with BRCA1, BRCA2 or PeutzJeghers syndrome (which
predispose to ovarian as well as breast cancer) were more, or less,
likely to be treated with tamoxifen than other breast cancers. A
greater proportion (above 90%) of tumours in BRCA1 patients are
oestrogen receptor-negative than occurs in other breast cancers
at the same ages (Lakhani et al, 2005), so there could be a bias
towards lower tamoxifen use in ovarian cancer patients than
controls, if choice of breast cancer therapy was influenced by
oestrogen receptor status. Over the study period, however, it is
unlikely that more than a quarter of breast cancers nationally were
tested for oestrogen receptor status (Dowsett M, pers comm), and
we estimate that at most a third of ovarian cancers after breast
Table 1 Descriptive characteristics of study subjects
Cases Controls
Characteristic No. % No. %
Country of residence
England 133 84.2 390 84.1
Wales 5 3.2 5 1.1
Scotland 20 12.7 69 14.9
Age at diagnosis of breast cancer (years)
29–44 63 39.9 133 28.7
45–49 46 29.1 157 33.8
50–54 49 31.0 174 37.5
Year of diagnosis of breast cancer
1983–84 40 25.3 97 20.9
1985–89 86 54.4 251 54.1
1990–94 32 20.3 116 25.0
Interval between diagnosis of breast cancer and ovarian cancer (or among controls: index date)
3 months–1 year 23 14.6 66 14.2
1–4 years 77 48.7 232 50.0
5–10 years 58 36.7 166 35.8
Menopausal status at diagnosis of breast cancer
Premenopausal 102 64.6 260 56.0
Peri- or postmenopausal 36 22.8 122 26.3
Unknown 20 12.7 82 17.7
Treatment of breast cancer
a
Radiotherapy 99 62.7 290 62.5
Non-hormonal chemotherapy 33 20.9 66 14.2
Tamoxifen 85 53.8 279 60.1
Other hormonal therapies 6 3.8 17 3.7
Total subjects 158 100.0 464 100.0
aAt least 3 months before date of diagnosis of ovarian cancer (or among controls, at least 3 months before index date).
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so the overall effect on the ovarian cancer relative risk in relation
to tamoxifen in our data should have been small.
Although risks of ovarian cancer were not related to non-
tamoxifen hormonal treatments for breast cancer or to radio-
therapy, there was a significantly raised risk in relation to
chemotherapy. On the basis of small numbers we could not
attribute this to a specific treatment, risks being similar for CMF as
for other (heterogeneous) non-hormonal chemotherapy. Published
data on ovarian cancer risks after chemotherapy for breast cancer
are based on small numbers of cases, but in an Italian cohort there
was a significant excess of ovarian cancer after chemotherapy for
breast cancer, most of which was CMF (Rubagotti et al, 1996), and
in an international pooled trials analysis there were more ovarian
cancers after polychemotherapy (38) than in a similar number of
breast cancer patients not so treated (28) (Early Breast Cancer
Trialists’ Collaborative Group, 2005). Breast cancer chemotherapy
includes several agents that are known carcinogens in humans
and/or animals (Tomatis et al, 1990), although it is unknown if any
can cause ovarian cancer specifically. The relation found with
Table 2 Risk of ovarian cancer in relation to tamoxifen treatment, duration, daily dose, cumulative dose and time since last use, all subjects, and
premenopausal subjects separately
a
All subjects
Cases Controls Premenopausal subjects All subjects
Tamoxifen treatment No. % No. % OR 95% CI OR 95% CI
Any tamoxifen treatment
No 73 46.2 185 39.9 1.0 1.0
Yes 85 53.8 279 60.1 1.0 (0.6–1.6) 0.9 (0.6–1.3)
Duration of treatment (years)
Not used 73 46.2 185 39.9 1.0 1.0
o2 32 20.3 128 27.6 0.8 (0.4–1.5) 0.7 (0.4–1.1)
2–4 19 12.0 92 19.8 0.6 (0.3–1.4) 0.5 (0.3–1.0)
b
5–12 16 10.1 44 9.5 0.8 (0.3–2.3) 1.2 (0.6–2.5)
Used, duration unknown 18 11.4 15 3.2 5.6 (1.9–16.5)
c 3.2 (1.5–6.7)
c
Heterogeneity : P¼0.64 Heterogeneity: P¼0.13
Trend OR/year
d 0.93 (0.81–1.07) 0.99 (0.90–1.09)
Average daily dose (mg)
e
Not used 73 46.2 185 39.9 1.0 1.0
20 51 32.3 188 40.5 0.9 (0.5–1.5) 0.8 (0.5–1.2)
40 17 10.8 68 14.7 0.8 (0.4–1.7) 0.7 (0.4–1.3)
Used, dose unknown 17 10.8 23 5.0 3.6 (1.3–10.1)
b 2.0 (1.0–4.1)
Heterogeneity : P¼0.79 Heterogeneity: P¼0.40
Trend OR/10mg per day
d 0.95 (0.79–1.15) 0.91 (0.78–1.06)
Cumulative dose (mg)
Not used 73 46.2 185 39.9 1.0 1.0
o7500 17 10.8 56 12.1 1.3 (0.6–2.8) 0.9 (0.5–1.7)
7500–14999 11 7.0 54 11.6 0.6 (0.2–1.4) 0.5 (0.3–1.1)
15000–29999 13 8.2 62 13.4 0.6 (0.2–1.4) 0.6 (0.3–1.1)
30000–59999 13 8.2 59 12.7 0.5 (0.2–1.4) 0.6 (0.3–1.3)
X60000 8 5.1 18 3.9 0.8 (0.2–2.8) 1.3 (0.5–3.3)
Used, dose unknown 23 14.6 30 6.5 3.5 (1.5–8.1)
c 2.1 (1.1–3.8)
b
Heterogeneity P¼0.34 Heterogeneity: P¼0.30
Trend OR/10000mg
d 0.95 (0.83–1.08) 0.98 (0.88–1.09)
Time since first known use
Not used 73 46.2 185 39.9 1.0 1.0
3 months–1 year 28 17.7 97 20.9 1.0 (0.5–1.9) 0.8 (0.5–1.4)
2–5 years 25 15.8 108 23.3 0.8 (0.4–1.6) 0.6 (0.4–1.1)
5–12 years 25 15.8 66 14.2 1.0 (0.4–2.4) 1.3 (0.7–2.5)
Used, time unknown 7 4.4 8 1.7 8.8 (1.0–81.1) 2.6 (0.9–7.8)
Heterogeneity: P¼0.95 Heterogeneity: P¼ 0.36
Trend OR/year
f 1.01 (0.82–1.24) 1.09 (0.93–1.27)
Time since last known use
Not used 73 46.2 185 39.9 1.0 1.0
Still on or o1 year 57 36.1 233 50.2 0.7 (0.4–1.2) 0.7 (0.5–1.1)
1–2 years 7 4.4 20 4.3 1.0 (0.3–4.2) 1.1 (0.4–2.7)
3–8 years 5 3.2 14 3.0 1.7 (0.4–6.8) 0.9 (0.3–2.6)
Used, time unknown 16 10.1 12 2.6 6.5 (2.0–20.9)
c 3.5 (1.6–8.0)
c
Heterogeneity: P¼0.34 Heterogeneity: P¼ 0.33
Trend OR/year
f 1.24 (0.88–1.74) 1.09 (0.87–1.36)
aUnless otherwise indicated, all tamoxifen-related exposures are those at least 3 months before the index date.
bPo0.05.
cPo0.01.
dTrend and heterogeneity tests exclude
missing value group, and include non-users as zero level.
eAveraged over period known to be on tamoxifen: 20¼10–24mg/day but mostly 20mg/day; 40¼25–42mg/day but
mostly 40mg/day.
fTrend excludes not used and missing value groups.
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consequence detailed data had not been collected to explore it
further. Our results suggest, however, that tamoxifen treatment of
premenopausal or perimenopausal women does not materially
affect ovarian cancer risk, but that non-hormonal chemotherapy
might do so.
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